Law360, New York (December 17, 2008) -- A federal judge has agreed to stay parts of discovery and bifurcate the trial in a patent infringement suit over hypertension drug Cardizem, weeks after defendant Sun Pharmaceutical Industries Ltd. introduced a slew of antitrust and patent misuse counterclaims into the suit.
Magistrate Judge Mark Falk of the U.S. District Court for the District of New Jersey signed a consent order Monday approving plaintiff Biovail Laboratories International SRL's requests related to discovery...
